Microenvironment of chronic lymphocytic leukaemia
Microenvironment of chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia: Transition to a new era
Ibrutinib as a frontline therapy in RESONATE2 trials for CLL
The role of the microenvironment and novel therapies in CLL
p62: Metabolism and the tumour microenvironment
Targeted therapy shows continued promise in patients whose tumours had NTRK gene fusions
Drugging “undruggable” transcription factor drivers in cancer
Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer
Elucidation and pharmacological targeting of tumour checkpoint dependencies
Identifying myeloid-driven biologies
Metastasis intiation mediated by thrombospondin 2
New technology can potentially overcome CAR T-cell limitations